UBI Banca has signed a distribution agreement with Pharus Sicav that will see Pharus Sicav’s entire range of funds distributed through the Italian bank.
The agreement will see UBI Banca distributing Pharus Sicav’s range of funds particularly focusing on the following three strategies:
Pharus Sicav Target, investing in a fixed income diversified portfolio – mainly selecting high yield bonds – aims at ensuring a high coupon flow.
Pharus Sicav Absolute Return, will invest in high quality corporate bonds with a cautious approach in terms of duration and credit risk with the aim to achieve positive returns in any market environment, containing volatility.
Pharus Sicav Biotech has the target to invest in equities issued by biopharmaceutical companies at the forefront of innovation in the medical field.
Pharus Sicav, chaired by Davide Pasquali (pictured), has €750m of assets under management.